Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 10, 2015, 92 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $6.99 to $188,811,000.00.

Highlighted Stocks Traded by Insiders:

Tyler Technologies (TYL) - FREE Research Report

Yeaman John M, who is Chairman of the Board at Tyler Technologies, sold 7,301 shares at $121.04 on June 10, 2015. Following this transaction, the Chairman of the Board owned 363,210 shares meaning that the stake was reduced by 1.97% with the 7,301-share transaction.

The shares most recently traded at $120.42, down $0.62, or 0.51% since the insider transaction. Historical insider transactions for Tyler Technologies go as follows:

  • 4-Week # shares sold: 17,294
  • 12-Week # shares sold: 17,294
  • 24-Week # shares sold: 22,294

The average volume for Tyler Technologies has been 187,700 shares per day over the past 30 days. Tyler Technologies has a market cap of $4.0 billion and is part of the technology sector and computer software & services industry. Shares are up 10.19% year-to-date as of the close of trading on Wednesday.

Tyler Technologies, Inc. provides integrated information management solutions and services for the public sector with a focus on local governments in the United States and internationally. The company has a P/E ratio of 66.3. Currently, there are 4 analysts who rate Tyler Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TYL - FREE

TheStreet Quant Ratings

rates Tyler Technologies as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

Tyler Technologies Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mednax (MD) - FREE Research Report

Wagner Karl B, who is Pres, American Anesthesiology at Mednax, sold 37,820 shares at $70.28 on June 10, 2015. Following this transaction, the Pres, American Anesthesiology owned 108,020 shares meaning that the stake was reduced by 25.93% with the 37,820-share transaction.

The shares most recently traded at $71.51, up $1.23, or 1.73% since the insider transaction. Historical insider transactions for Mednax go as follows:

  • 4-Week # shares sold: 66,469
  • 12-Week # shares sold: 66,469
  • 24-Week # shares sold: 181,517

The average volume for Mednax has been 548,500 shares per day over the past 30 days. Mednax has a market cap of $6.6 billion and is part of the health care sector and health services industry. Shares are up 7.2% year-to-date as of the close of trading on Wednesday.

MEDNAX, Inc., together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company has a P/E ratio of 21.6. Currently, there are 10 analysts who rate Mednax a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MD - FREE

TheStreet Quant Ratings

rates Mednax as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Mednax Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Kemet (KEM) - FREE Research Report

Borruso Joseph Vincent, who is Director at Kemet, bought 1,000 shares at $3.13 on June 10, 2015. Following this transaction, the Director owned 47,867 shares meaning that the stake was boosted by 2.13% with the 1,000-share transaction.

The shares most recently traded at $3.03, down $0.10, or 3.27% since the insider transaction. Historical insider transactions for Kemet go as follows:

  • 4-Week # shares bought: 1,000
  • 12-Week # shares bought: 1,000
  • 24-Week # shares bought: 1,000

The average volume for Kemet has been 163,600 shares per day over the past 30 days. Kemet has a market cap of $139.8 million and is part of the technology sector and electronics industry. Shares are down 27.86% year-to-date as of the close of trading on Wednesday.

KEMET Corporation, together with its subsidiaries, manufactures and sells various capacitors under the KEMET brand worldwide. The company operates through two segments, Film and Electrolytic Business Group and Solid Capacitors Business Group. Currently, there are no analysts who rate Kemet a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on KEM - FREE

TheStreet Quant Ratings

rates Kemet as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full

Kemet Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.